- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 207/12 - Oxygen or sulfur atoms
Patent holdings for IPC class C07D 207/12
Total number of patents in this class: 719
10-year publication summary
46
|
43
|
66
|
44
|
53
|
64
|
47
|
35
|
47
|
20
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Sanofi | 4055 |
23 |
Bristol-myers Squibb Company | 4898 |
20 |
Journey Medical Corporation | 94 |
19 |
Novartis AG | 10849 |
18 |
Takeda Pharmaceutical Company Limited | 2713 |
18 |
Bodor Laboratories, Inc. | 58 |
11 |
F. Hoffmann-La Roche AG | 7925 |
10 |
Boehringer Ingelheim International GmbH | 4650 |
10 |
Integrative Research Laboratories Sweden AB | 34 |
8 |
Merck Sharp & Dohme LLC | 3748 |
8 |
Chiesi Farmaceutici S.p.A. | 969 |
7 |
Hoffmann-La Roche Inc. | 3418 |
6 |
Alnylam Pharmaceuticals, Inc. | 1151 |
6 |
Astellas Pharma Inc. | 1088 |
6 |
Cayman Chemical Company, Incorporated | 68 |
6 |
Correvio International Sàrl | 22 |
6 |
Recurium IP Holdings, LLC | 134 |
6 |
Gen1e Lifesciences Inc. | 26 |
6 |
AstraZeneca AB | 2909 |
5 |
Centre National de La Recherche Scientifique | 10418 |
5 |
Other owners | 515 |